Eisai Deal Puts Epizyme In Position To Advance Lead Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal with Eisai on epigenetic enzymes is collaborative, whereas in recent tie up with GSK, Epizyme gave up control of development and commercialization of select histone methyltransferases.
You may also be interested in...
Eisai Cancer Subsidiary H3 Pushes Toward The Clinic
H3 Biomedicine is using publicly available cancer genomics data to discover compounds that could treat small subsets of patients.
Epizyme Builds A Cancer Company At Mach Speed
Epizyme’s recent alliance with Celgene validates industry’s interest in histone methyltransferase inhibitors, a kinase-like class of epigenetic enzymes. Celgene’s willingness to cede US rights in return for access to preclinical assets belies HMTs’ novelty and helps to position Epizyme for potential success as a US-focused oncology company. Despite the strong start, it won’t be easy.
Epigenetic Modifiers Take Center Stage, Big Pharma Takes Notice
Epigenetic modifiers are targeting a widening range of indications as growing knowledge of the underlying biology enables improved agents and therapeutic strategies. Nonetheless, issues of selectivity, toxicity, and finding adequate biomarkers still prevent the field from reaching its full potential.